Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company focused on developing pelareorep, a proprietary immunotherapy derived from a non-pathogenic reovirus isolate. Pelareorep selectively replicates in cancer cells, inducing tumor lysis and promoting an inflamed tumor microenvironment by stimulating innate and adaptive immune responses, including expansion of tumor-infiltrating lymphocytes and upregulation of key chemokines and PD-L1. This intravenous agent transforms immunologically 'cold' tumors resistant to standard therapies into 'hot' ones responsive to immune attack, enhancing the efficacy of chemotherapy, checkpoint inhibitors, and other standard-of-care treatments. The company targets solid tumors and hematological malignancies across multiple indications, such as HR+/HER2- breast cancer and pancreatic cancer, through partnerships with academic and pharmaceutical collaborators. Founded in 1998 and headquartered in Calgary, Alberta, Oncolytics Biotech Inc. advances pelareorep in clinical pipelines to harness the immune system against cancer.